

Gypenoside Inhibits Gastric Cancer Proliferation by Suppressing Glycolysis via the Hippo Pathway

Li Pan^{1,2,3#}, Bingxue Lan^{1,2#}, Shoumin Li^{1,2,4#}, Yong Jin⁵, Miaomiao Cui^{1,2,6}, Ying Xia⁷, Sixi Wei^{1,2}, Hai Huang^{1,2*}

¹ Center for Clinical Laboratories, The Affiliated Hospital of Guizhou Medical University, Guiyang, 550004, China

² School of Clinical Laboratory Science, Guizhou Medical University, Guiyang, 550004, China

³ Department of Clinical Laboratory, Guiyang Nanming District People's Hospital, Guiyang, 550002, China

⁴ Department of Clinical Laboratory, Liu-panshui Municipal People's Hospital, Liupanshui, 553000, China

⁵ Department of Laboratory Medicine, The Second People's Hospital of Guizhou Province, Guiyang, 550004, China

⁶ Department of Clinical Laboratory, Guiyang Second People's Hospital, Guiyang, 550081, China

⁷ Department of Clinical Laboratory, The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, 550001, China

[#]These authors have contributed equally to this work.


*** Correspondence:**

Hai Huang

huanghai828@gmc.edu.cn

Supplementary Figures

Supplementary Figure 1



Supplementary Figure 1 The GO analysis of RNA-seq after Gyp treatment. (A-C) GO analysis for biological processes (BP), cellular components (CC), and molecular functions (MF).

Supplementary Tables

Supplementary Table 1 All RT-qPCR primers (5' – 3') in this manuscript

Gene Name	Forward Primer	Reverse Primer
GLUT1	TCTGGCATCAACGCTGTCTTC	CGATACCGGAGCCAATGGT
LDHA	ATGGCAACTCTAAAGGATCAGC	CCAACCCCAACAACCTGTAATCT
PKM2	ATGTCGAAGCCCCATAGTGAA	TGGGTGGTGAATCAATGTCCA
PFK	GGTGCCCGTGTCTTCTTTGT	AAGCATCATCGAAACGCTCTC
G6PD	CGAGGCCGTCACCAAGAAC	GTAGTGGTCGATGCGGTAGA
HPRT	ATGGCGACCCGCAGCCCT	CCATGAGGAATAAACACCCT


Supplementary Table 2 The information of primary antibody

Antibodies	Company	Catalog Number	Host	Working Concentration
PCNA	ProteinTech	10205-2-AP	Rabbit	1:5000
BAX	ProteinTech	50599-2-Ig	Rabbit	1:2000
Bcl2	ProteinTech	68103-1-Ig	Rabbit	1:4000
E-cadherin	ProteinTech	20874-1-AP	Rabbit	1:2000
N-cadherin	ProteinTech	22018-1-AP	Rabbit	1:1000
TAZ	ProteinTech	23306-1-AP	Rabbit	1:1000
YAP (S127)	Huabio	ET1611-69	Rabbit	1:1000
LATS1/2	Huabio	ER65865	Rabbit	1:2000
Vimentin	Cell Signaling Technology	5741S	Rabbit	1:2000
Ki67	Abcam	ab16667	Rabbit	1:200
GAPDH	Bioworld	AP0063	Rabbit	1:10000

Supplementary Table 3 Clinical chemistry parameters for therapy of Gyp *in vivo*


Groups	ALT (U/L)	AST (U/L)	CREA ($\mu\text{mol/L}$)	BUN (mg/dL)
Control	81.67 ± 14.01	154.7 ± 41.20	13.00 ± 0.800	10.09 ± 0.5866
Gyp	48.67 ± 11.72	185.0 ± 39.15	13.70 ± 2.722	9.743 ± 1.669
Normal reference values	10.06-96.47	36.31-235.48	10.91-85.09	10.81-34.74

The raw protein data of this manuscript



*: nonspecific bands

HGC-27



*: nonspecific bands